Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2021-04-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于贝达药业股份有限公司2020年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled '中信证券股份有限公司关于贝达药业股份有限公司2020年度持续督导跟踪报告' which translates to 'CITIC Securities Co., Ltd. 2020 Annual Continuous Supervision Tracking Report on Betta Pharmaceuticals Co., Ltd.' The content includes detailed supervision work overview, problem identification and measures taken, company and shareholder commitment fulfillment, regulatory measures and responses, and other related supervisory information. It is a comprehensive report on the continuous supervision activities by the sponsor institution over the course of the year 2020. The document length is 8110 characters, indicating it is a full report rather than a brief announcement. The nature of the document is a regulatory and supervisory report related to the sponsor's ongoing monitoring duties, not a financial statement or earnings release. It does not fit the categories of Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Audit Report (AR). It is also not a simple announcement or certification. The document is best classified under Regulatory Filings (RNS) as it is a regulatory compliance and supervision report that does not fit other specific categories.
2021-04-16 Chinese
中信证券股份有限公司关于贝达药业股份有限公司2020年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-evaluation report for the year 2020 of Betta Pharmaceuticals Co., Ltd., with verification opinions from CITIC Securities Co., Ltd., the sponsoring institution. It discusses the scope, standards, and results of internal control evaluations, including financial and non-financial control defects, governance, risk assessment, and internal audit. The document is detailed and contains substantive content about internal control systems and their effectiveness, not merely an announcement or certification. It is not a full annual report (10-K) but a specific audit-related report focusing on internal control evaluation and verification. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report on internal controls, not the full annual report or other categories. The document length (over 10,000 characters) and detailed content support this classification with high confidence. FY 2020
2021-04-16 Chinese
中信证券股份有限公司关于贝达药业股份有限公司2020年度持续督导工作定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2020年度持续督导工作定期现场检查报告" which translates to "2020 Annual Continuous Supervision Work Regular On-site Inspection Report" by CITIC Securities for Betta Pharmaceuticals. The content details a comprehensive on-site inspection covering company governance, internal control, information disclosure, protection mechanisms, use of raised funds, performance, shareholder commitments, and other important matters. It includes detailed findings and compliance checks rather than a summary or announcement. The document length is 3964 characters, which is relatively short but contains substantive inspection results and opinions rather than just an announcement or certification. This type of document is a standalone audit or inspection report related to regulatory supervision and internal controls, fitting the category of Audit Report / Information (AR). It is not an Annual Report (10-K), Interim Report (IR), or a simple announcement (RPA or RNS). FY 2020
2021-04-16 Chinese
2020年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2020年度股东大会决议公告" which translates to "2020 Annual General Meeting Resolution Announcement." It details the resolutions passed at the 2020 Annual General Meeting (AGM) of the company, including voting results on various agenda items such as the board report, supervisory report, financial report, annual report, profit distribution plan, remuneration, auditor appointment, and financing proposals. The document includes attendance details, voting methods, and legal opinions confirming the validity of the meeting and resolutions. It does not contain the full annual report or financial statements themselves but reports on the outcomes of the AGM. The document length is 4485 characters, which is relatively short and consistent with an announcement of AGM resolutions rather than the full report or presentation materials. Therefore, the document fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-04-15 Chinese
2020年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2020 Annual General Meeting (AGM) of Betta Pharmaceuticals Co., Ltd. It details the convening, attendance, agenda, voting procedures, and results of the AGM. The document focuses on the legality and validity of the AGM process and voting outcomes, rather than presenting the company's financial performance or management discussion. It is not the annual report itself, nor an earnings release or management report. It is a legal opinion related to the AGM proceedings and voting results. This type of document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and validates the AGM procedures.
2021-04-15 Chinese
关于召开2020年度股东大会通知的更正暨提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the correction and supplementary information for the notice of the 2020 Annual General Meeting (AGM) of the company 贝达药业股份有限公司. It includes information about the meeting agenda, voting proposals, voting procedures, registration details, and proxy forms. The document does not contain the actual annual report or financial statements but refers to them as agenda items to be discussed and voted on at the AGM. The document is primarily about the AGM meeting notice and related procedural information, not the report itself. Therefore, it fits the category of AGM Information (AGM-R). The document length is over 7,000 characters, which is consistent with a detailed AGM notice rather than a brief announcement or a report publication announcement.
2021-04-12 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.